1. Home
  2. ETON vs IMMP Comparison

ETON vs IMMP Comparison

Compare ETON & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$26.96

Market Cap

683.7M

Sector

Health Care

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.55

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
IMMP
Founded
2017
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.7M
58.2M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
ETON
IMMP
Price
$26.96
$0.55
Analyst Decision
Strong Buy
Hold
Analyst Count
3
3
Target Price
$39.33
$5.50
AVG Volume (30 Days)
465.8K
867.5K
Earning Date
05-12-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$79,950,000.00
N/A
Revenue This Year
$40.90
$417.85
Revenue Next Year
$47.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
104.94
N/A
52 Week Low
$13.09
$0.29
52 Week High
$27.19
$3.53

Technical Indicators

Market Signals
Indicator
ETON
IMMP
Relative Strength Index (RSI) 72.35 36.54
Support Level $16.23 N/A
Resistance Level N/A $1.75
Average True Range (ATR) 1.19 0.06
MACD 0.07 0.10
Stochastic Oscillator 94.39 36.05

Price Performance

Historical Comparison
ETON
IMMP

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: